Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XL102 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors

NCT04726332 is registered in ClinicalTrials.gov with Exelixis as lead sponsor.

NCT NCT04726332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04726332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XL102 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Exelixis
Phase
Phase 1
Overall status
Terminated
Start date
February 10, 2021
Completion date
May 2, 2024
Enrollment
52 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial ovarian cancer, hormone receptor positive breast carcinoma, metastatic castration-resistant prostate cancer, neoplasm malignant, triple negative breast cancer